• Mashup Score: 14

    Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the U.S., have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in patients with B cell lymphomas. Individualized microbiome information retrieved from patients’ gut microbiomes prior to initiation of CAR T therapy could accurately predict…

    Tweet Tweets with this article
    • #Gutmicrobiome can play key role in response to CAR-#Tcell cancer immunotherapy @DKFZ @NatureMedicine https://t.co/KQSqFKypY3